EdgarLookup

General Motors Co — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that General Motors Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
1.5%
Profit Margin
Net income ÷ revenue
1%
Return on Assets
Net income ÷ assets
3.57x
Debt-to-Equity
Total liabilities ÷ equity
-1.3%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $185.02B Jan 27, 2026
FY2025 Dec 31, 2024 $187.44B Jan 27, 2026
FY2025 Dec 31, 2023 $171.84B Jan 27, 2026
FY2024 Dec 31, 2022 $156.74B Jan 28, 2025
FY2023 Dec 31, 2021 $127.00B Jan 30, 2024
FY2022 Dec 31, 2020 $122.49B Jan 31, 2023
FY2019 Dec 31, 2019 $30.83B Feb 5, 2020
FY2019 Sep 30, 2019 $35.47B Feb 5, 2020
FY2019 Jun 30, 2019 $36.06B Feb 5, 2020
FY2019 Mar 31, 2019 $34.88B Feb 5, 2020

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $167.97B Jan 27, 2026
FY2025 Dec 31, 2024 $171.61B Jan 27, 2026
FY2025 Dec 31, 2023 $157.66B Jan 27, 2026
FY2024 Dec 31, 2022 $143.98B Jan 28, 2025
FY2023 Dec 31, 2021 $113.59B Jan 30, 2024
FY2022 Dec 31, 2020 $108.67B Jan 31, 2023
FY2021 Dec 31, 2019 $122.70B Feb 2, 2022
FY2020 Dec 31, 2018 $133.05B Feb 10, 2021

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $133.45B Feb 6, 2018
FY2017 Dec 31, 2016 $140.21B Feb 6, 2018
FY2017 Dec 31, 2015 $129.86B Feb 6, 2018
FY2016 Dec 31, 2014 $151.09B Feb 7, 2017
FY2015 Dec 31, 2013 $152.09B Feb 3, 2016
FY2014 Dec 31, 2012 $150.30B Feb 4, 2015
FY2013 Dec 31, 2011 $148.87B Feb 6, 2014
FY2012 Dec 31, 2010 $135.31B Feb 15, 2013
FY2011 Dec 31, 2009 $57.47B Feb 27, 2012
FY2011 Jul 9, 2009 $47.12B Feb 27, 2012

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2012 Dec 31, 2012 ($3.14B) Feb 15, 2013
FY2012 Sep 30, 2012 $4.33B Feb 15, 2013
FY2012 Jun 30, 2012 $4.45B Feb 15, 2013
FY2012 Mar 31, 2012 $4.42B Feb 15, 2013
FY2011 Dec 31, 2011 $4.42B Feb 27, 2012
FY2011 Sep 30, 2011 $4.59B Feb 27, 2012
FY2011 Jun 30, 2011 $5.25B Feb 27, 2012
FY2011 Mar 31, 2011 $4.21B Feb 27, 2012
FY2011 Dec 31, 2010 $3.58B Feb 27, 2012
FY2011 Sep 30, 2010 $4.47B Feb 27, 2012

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.70B Jan 27, 2026
FY2025 Dec 31, 2024 $6.01B Jan 27, 2026
FY2025 Dec 31, 2023 $10.13B Jan 27, 2026
FY2024 Dec 31, 2022 $9.93B Jan 28, 2025
FY2023 Dec 31, 2021 $10.02B Jan 30, 2024
FY2022 Dec 31, 2020 $6.43B Jan 31, 2023
FY2019 Dec 31, 2019 ($194.00M) Feb 5, 2020
FY2019 Sep 30, 2019 $2.35B Feb 5, 2020
FY2019 Jun 30, 2019 $2.42B Feb 5, 2020
FY2019 Mar 31, 2019 $2.16B Feb 5, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.91B Jan 27, 2026
FY2025 Dec 31, 2024 $12.78B Jan 27, 2026
FY2025 Dec 31, 2023 $9.30B Jan 27, 2026
FY2024 Dec 31, 2022 $10.32B Jan 28, 2025
FY2023 Dec 31, 2021 $9.32B Jan 30, 2024
FY2022 Dec 31, 2020 $6.63B Jan 31, 2023
FY2021 Dec 31, 2019 $5.48B Feb 2, 2022
FY2020 Dec 31, 2018 $4.45B Feb 10, 2021
FY2019 Dec 31, 2017 $8.66B Feb 5, 2020
FY2018 Dec 31, 2016 $8.69B Feb 6, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2013 Dec 31, 2013 $7.20B Feb 6, 2014
FY2012 Dec 31, 2012 $7.37B Feb 15, 2013
FY2011 Dec 31, 2011 $8.12B Feb 27, 2012
FY2011 Dec 31, 2010 $6.96B Feb 27, 2012
FY2011 Dec 31, 2009 $3.03B Feb 27, 2012
FY2011 Jul 9, 2009 $3.02B Feb 27, 2012

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2021 Dec 31, 2021 $8.55B Feb 2, 2022
FY2021 Dec 31, 2020 $7.04B Feb 2, 2022
FY2021 Dec 31, 2019 $8.49B Feb 2, 2022
FY2020 Dec 31, 2018 $9.65B Feb 10, 2021
FY2019 Dec 31, 2017 $9.57B Feb 5, 2020
FY2018 Dec 31, 2016 $10.35B Feb 6, 2019
FY2017 Dec 31, 2015 $11.89B Feb 6, 2018
FY2016 Dec 31, 2014 $12.16B Feb 7, 2017
FY2015 Dec 31, 2013 $12.38B Feb 3, 2016
FY2014 Dec 31, 2012 $14.03B Feb 4, 2015

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $26.87B Jan 27, 2026
FY2025 Dec 31, 2024 $20.13B Jan 27, 2026
FY2025 Dec 31, 2023 $20.93B Jan 27, 2026
FY2024 Dec 31, 2022 $16.04B Jan 28, 2025
FY2023 Dec 31, 2021 $15.19B Jan 30, 2024
FY2022 Dec 31, 2020 $16.67B Jan 31, 2023
FY2021 Dec 31, 2019 $15.02B Feb 2, 2022
FY2020 Dec 31, 2018 $15.26B Feb 10, 2021
FY2019 Dec 31, 2017 $17.33B Feb 5, 2020
FY2018 Dec 31, 2016 $16.61B Feb 6, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $9.30B Jan 27, 2026
FY2025 Dec 31, 2024 $10.83B Jan 27, 2026
FY2025 Dec 31, 2023 $10.97B Jan 27, 2026
FY2024 Dec 31, 2022 $9.24B Jan 28, 2025
FY2023 Dec 31, 2021 $7.51B Jan 30, 2024
FY2022 Dec 31, 2020 $5.30B Jan 31, 2023
FY2021 Dec 31, 2019 $7.59B Feb 2, 2022
FY2020 Dec 31, 2018 $8.76B Feb 10, 2021
FY2019 Dec 31, 2017 $8.45B Feb 5, 2020
FY2018 Dec 31, 2016 $8.38B Feb 6, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $281.28B Jan 27, 2026
FY2025 Dec 31, 2024 $279.76B Jan 27, 2026
FY2025 Dec 31, 2023 $273.06B Jan 27, 2026
FY2024 Dec 31, 2022 $264.04B Jan 28, 2025
FY2023 Dec 31, 2021 $244.72B Jan 30, 2024
FY2022 Dec 31, 2020 $235.19B Jan 31, 2023
FY2021 Dec 31, 2019 $228.04B Feb 2, 2022
FY2020 Dec 31, 2018 $227.34B Feb 10, 2021
FY2019 Dec 31, 2017 $212.48B Feb 5, 2020
FY2018 Dec 31, 2016 $221.69B Feb 6, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $218.12B Jan 27, 2026
FY2025 Dec 31, 2024 $214.17B Jan 27, 2026
FY2024 Dec 31, 2023 $204.76B Jan 28, 2025
FY2023 Dec 31, 2022 $191.75B Jan 30, 2024
FY2022 Dec 31, 2021 $178.90B Jan 31, 2023
FY2021 Dec 31, 2020 $185.52B Feb 2, 2022
FY2020 Dec 31, 2019 $182.08B Feb 10, 2021
FY2019 Dec 31, 2018 $184.56B Feb 5, 2020
FY2018 Dec 31, 2017 $176.28B Feb 6, 2019
FY2017 Dec 31, 2016 $177.62B Feb 6, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $61.12B Jan 27, 2026
FY2025 Dec 31, 2024 $63.07B Jan 27, 2026
FY2024 Dec 31, 2023 $64.29B Jan 28, 2025
FY2023 Dec 31, 2022 $67.79B Jan 30, 2024
FY2022 Dec 31, 2021 $59.74B Jan 31, 2023
FY2021 Dec 31, 2020 $45.03B Feb 2, 2022
FY2020 Dec 31, 2019 $41.79B Feb 10, 2021
FY2019 Dec 31, 2018 $38.86B Feb 5, 2020
FY2018 Dec 31, 2017 $35.00B Feb 6, 2019
FY2017 Dec 31, 2016 $43.84B Feb 6, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.90B Jan 27, 2026
FY2025 Dec 31, 2024 $1.90B Jan 27, 2026
FY2024 Dec 31, 2023 $1.90B Jan 28, 2025
FY2023 Dec 31, 2022 $1.90B Jan 30, 2024
FY2022 Dec 31, 2021 $1.90B Jan 31, 2023
FY2021 Dec 31, 2020 $1.90B Feb 2, 2022
FY2020 Dec 31, 2019 $1.90B Feb 10, 2021
FY2019 Dec 31, 2018 $1.90B Feb 5, 2020
FY2018 Dec 31, 2017 $1.90B Feb 6, 2019
FY2017 Dec 31, 2016 $1.90B Feb 6, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $51.52B Jan 27, 2026
FY2025 Dec 31, 2024 $53.47B Jan 27, 2026
FY2024 Dec 31, 2023 $55.39B Jan 28, 2025
FY2023 Dec 31, 2022 $49.25B Jan 30, 2024
FY2022 Dec 31, 2021 $41.94B Jan 31, 2023
FY2021 Dec 31, 2020 $31.96B Feb 2, 2022
FY2020 Dec 31, 2019 $26.86B Feb 10, 2021
FY2019 Dec 31, 2018 $22.32B Feb 5, 2020
FY2018 Jan 1, 2018 $16.58B Feb 6, 2019
FY2018 Dec 31, 2017 $17.63B Feb 6, 2019

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $20.95B Jan 27, 2026
FY2025 Dec 31, 2024 $19.87B Jan 27, 2026
FY2024 Dec 31, 2023 $18.85B Jan 28, 2025
FY2023 Dec 31, 2022 $19.15B Jan 30, 2024
FY2022 Dec 31, 2021 $20.07B Jan 31, 2023
FY2021 Dec 31, 2020 $19.99B Feb 2, 2022
FY2020 Dec 31, 2019 $19.07B Feb 10, 2021
FY2019 Dec 31, 2018 $20.84B Feb 5, 2020
FY2018 Dec 31, 2017 $15.51B Feb 6, 2019
FY2017 Dec 31, 2016 $12.57B Feb 6, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 3 Jan 27, 2026
FY2025 Dec 31, 2024 6 Jan 27, 2026
FY2025 Dec 31, 2023 7 Jan 27, 2026
FY2024 Dec 31, 2022 6 Jan 28, 2025
FY2023 Dec 31, 2021 6 Jan 30, 2024
FY2022 Dec 31, 2020 4 Jan 31, 2023
FY2021 Dec 31, 2019 4 Feb 2, 2022
FY2020 Dec 31, 2018 5 Feb 10, 2021
FY2019 Dec 31, 2017 (2) Feb 5, 2020
FY2016 Dec 31, 2016 1 Feb 7, 2017

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 3 Jan 27, 2026
FY2025 Dec 31, 2024 6 Jan 27, 2026
FY2025 Dec 31, 2023 7 Jan 27, 2026
FY2024 Dec 31, 2022 6 Jan 28, 2025
FY2023 Dec 31, 2021 6 Jan 30, 2024
FY2022 Dec 31, 2020 4 Jan 31, 2023
FY2021 Dec 31, 2019 4 Feb 2, 2022
FY2020 Dec 31, 2018 5 Feb 10, 2021
FY2019 Dec 31, 2017 (2) Feb 5, 2020
FY2016 Dec 31, 2016 1 Feb 7, 2017

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 904.00M Jan 27, 2026
FY2025 Dec 31, 2024 995.00M Jan 27, 2026
FY2024 Dec 31, 2023 1.20B Jan 28, 2025
FY2023 Dec 31, 2022 1.40B Jan 30, 2024
FY2022 Dec 31, 2021 1.50B Jan 31, 2023
FY2021 Dec 31, 2020 1.40B Feb 2, 2022
FY2020 Dec 31, 2019 1.40B Feb 10, 2021
FY2019 Dec 31, 2018 1.40B Feb 5, 2020
FY2018 Dec 31, 2017 1.40B Feb 6, 2019
FY2017 Dec 31, 2016 1.50B Feb 6, 2018

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2014 Dec 31, 2014 $1.93B Feb 4, 2015
FY2014 Dec 31, 2013 $0 Feb 4, 2015
FY2014 Dec 31, 2012 $0 Feb 4, 2015